Form 4: Mersana Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Lawrence M. Alleva acquired 55,000 stock options in Mersana Therapeutics, Inc. on June 11, 2024.
Summary
- Lawrence M. Alleva, a director of Mersana Therapeutics, Inc., acquired 55,000 stock options on June 11, 2024.
- The options have an exercise price of $2.26.
- The options vest on the earlier of June 11, 2025, or the date of the 2025 Annual Meeting of Stockholders, contingent upon continuous service with the issuer.
- The options expire on June 10, 2034.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (directors, officers, or those holding more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of transaction: Director acquired stock options. |
| 06/11/2025 | Vesting date of stock options (or date of 2025 Annual Meeting of Stockholders). |
| 06/10/2034 | Expiration date of stock options. |
| 06/12/2024 | Date of signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.